However, the entry of biosimilars for Humira and potential future competition for Stelara present ongoing challenges. In the aesthetics segment, AbbVie faces headwinds due to macroeconomic factors ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

In terms of how Stelara’s loss of exclusivity is likely to play out, “we’ve talked about the Humira erosion curve being probably the best thing to model,” Jennifer Taubert, J&J’s ...

Tariffs and price inflation for specialty medications will increase costs, according to research from Vizient.

While speaking at the conference, J&J’s CEO, Joaquin Duato, indicated the company’s willingness to protect Stelara ... blockbuster adalimumab therapy, Humira. The launch of cheaper adalimumab ...

Investors are also waiting to see how generic competition shakes out for Stelara. Using AbbVie's (ABBV) Humira as a guide, the company and analysts alike see potential for a muted impact.

Humira’s success is down to its incredible ... showing it outperformed Janssen's Stelara. Cosentyx has been one the most successful launches of the last few years, and is set to be a dominant ...